- Home
- ABSI vs ESPR Comparison
ABSI vs ESPR Comparison
Compare ABSI & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABSI
- ESPR
- Stock Information
- Founded
- ABSI 2011
- ESPR 2008
- Country
- ABSI United States
- ESPR United States
- Employees
- ABSI N/A
- ESPR N/A
- Industry
- ABSI Biotechnology: Pharmaceutical Preparations
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- ABSI Health Care
- ESPR Health Care
- Exchange
- ABSI Nasdaq
- ESPR Nasdaq
- Market Cap
- ABSI 353.8M
- ESPR 305.0M
- IPO Year
- ABSI 2021
- ESPR 2013
- Fundamental
- Price
- ABSI $3.01
- ESPR $1.69
- Analyst Decision
- ABSI Strong Buy
- ESPR Buy
- Analyst Count
- ABSI 6
- ESPR 7
- Target Price
- ABSI $7.83
- ESPR $6.36
- AVG Volume (30 Days)
- ABSI 4.4M
- ESPR 4.2M
- Earning Date
- ABSI 03-18-2025
- ESPR 03-04-2025
- Dividend Yield
- ABSI N/A
- ESPR N/A
- EPS Growth
- ABSI N/A
- ESPR N/A
- EPS
- ABSI N/A
- ESPR N/A
- Revenue
- ABSI $4,534,000.00
- ESPR $332,314,000.00
- Revenue This Year
- ABSI $257.06
- ESPR $5.51
- Revenue Next Year
- ABSI $112.29
- ESPR $1.42
- P/E Ratio
- ABSI N/A
- ESPR N/A
- Revenue Growth
- ABSI N/A
- ESPR 185.66
- 52 Week Low
- ABSI $2.45
- ESPR $1.47
- 52 Week High
- ABSI $6.72
- ESPR $3.94
- Technical
- Relative Strength Index (RSI)
- ABSI 38.78
- ESPR 49.78
- Support Level
- ABSI $2.81
- ESPR $1.47
- Resistance Level
- ABSI $3.15
- ESPR $1.61
- Average True Range (ATR)
- ABSI 0.23
- ESPR 0.12
- MACD
- ABSI -0.02
- ESPR 0.02
- Stochastic Oscillator
- ABSI 33.61
- ESPR 56.41
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.